McCann Healthcare Loses Avodart to Cramer-Krasselt

McCann Healthcare has lost the Avodart account, a GlaxoSmithKline product that helps relieve problems associated with an enlarged prostate. The account has landed with Cramer-Krasselt, we’ve confirmed with a source close to the matter.

We’re told that this does not affect other GSK accounts held by McCann.

More: “Curt Detweiler to EVP/ECD at McCann North America”